Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

POSITive: Prospective Observational Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies

NCT06321640 is registered in ClinicalTrials.gov with European Institute of Oncology as lead sponsor.

NCT NCT06321640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06321640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
POSITive: Prospective Observational Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies
Lead sponsor
European Institute of Oncology
Phase
Observational
Overall status
Unknown status
Start date
July 8, 2022
Completion date
December 31, 2025
Enrollment
265 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer, head and neck cancer, liver metastases, lung cancer, lung metastases, melanoma, urothelial carcinoma